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 Background Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined 
concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with 
untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on 
brain metastases and systemic activity.
 Methods Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo 
(n = 40) or erlotinib (100 mg, n = 40) given concurrently with WBRT (20 Gy in 5 fractions). Following WBRT, patients 
continued with placebo or erlotinib (150 mg) until disease progression. The primary end point was neurological pro-
gression-free survival (nPFS); hazard ratios (HRs) were calculated using Cox regression. All P values were two-sided.
 Results Fifteen patients (37.5%) from each arm were alive and without neurological progression 2 months after WBRT. 
Median nPFS was 1.6 months in both arms; nPFS HR 0.95 (95% CI = 0.59 to1.54; P = .84). Median overall survival 
(OS) was 2.9 and 3.4 months in the placebo and erlotinib arms; HR 0.95 (95% CI = 0.58 to 1.55; P = .83). The fre-
quency of epidermal growth factor receptor (EGFR) mutations was low with only 1 of 35 (2.9%) patients with 
available samples had activating EGFR-mutations. Grade 3/4 adverse event rates were similar between the two 
groups (70.0% in each arm), except for rash 20.0% (erlotinib) vs 5.0% (placebo), and fatigue 17.5% vs 35.0%. No 
statistically significant quality of life differences were found.
 Conclusions Our study showed no advantage in nPFS or OS for concurrent erlotinib and WBRT followed by maintenance erlo-
tinib in patients with predominantly EGFR wild-type NSCLC and multiple brain metastases compared to placebo. 
Future studies should focus on the role of erlotinib with or without WBRT in patients with EGFR mutations.
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Up to 40% of patients with non-small cell lung cancer (NSCLC) 
develop brain metastases (BM), which are associated with poor 
outcome (median survival <5  months) (1–3). Treatment options 
include whole-brain radiotherapy (WBRT) with or without corti-
costeroids. Modifying the radiation dose or fractionation or com-
bining radiotherapy with radiosensitizers have not substantially 
improved prognosis (4–10). More than half of patients treated with 
WBRT ultimately die of progressive systemic disease (11–13).
Erlotinib, an epidermal growth factor receptor (EGFR) pathway 
inhibitor, is currently approved as first-line treatment for advanced 
NSCLC patients harboring EGFR mutations, and, as maintenance, 
second-line or third-line treatments following chemotherapy (14–
17). Pre-clinical data show that erlotinib enhances the inhibitory 
effect of ionizing radiation in lung cancer, and it crosses the blood-
brain barrier, so it could be used to provide sufficient radiosensitiz-
ing and therapeutic level in the brain (18–22).
To exploit the potential radiosensitizing properties, the direct 
effect on brain metastases, and systemic activity of erlotinib, we 
examined the role of erlotinib given concurrently with WBRT, 
then as maintenance.
Methods
Patients
Inclusion criteria were: histologically or cytologically confirmed 
NSCLC and newly diagnosed multiple BM documented by MRI or 
contrast CT scan, but did not require immediate chemotherapy for 
symptom control; aged 18–76 years; no previous cranial radiother-
apy; at least 28 days since any chemotherapy; Glasgow Coma Score 
of 14 and greater; Karnofsky performance status of 70 and greater; 
3 or fewer sites of extra-cranial metastases; adequate renal and liver 
function; negative pregnancy test; and age-modified (age cut-off 
76 years instead of 66 years) Radiation Therapy Oncology Group 
Recursive Partitioning Analysis (RTOG RPA) class I and II (class I is 
KPS ≥ 70, controlled primary tumor, metastases to brain only, and 
class  II is uncontrolled primary tumor, or primary controlled, but 
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metastases to brain and other sites) (23). Patients with other previ-
ous or current malignant disease, solitary brain metastasis suitable 
for stereotactic radiosurgery or surgical resection, previously treated 
with any EGFR anti-cancer therapy or currently being treated with 
Cox II inhibitor were excluded.
Patients were randomly assigned to receive erlotinib or placebo 
after telephoning the trials center. Randomization was stratified 
using: presence/absence of extra-cranial metastases, number of sites 
of brain metastases, age-modified RTOG RPA score, and center.
Study Design and Treatment
We performed a two-stage randomized, multicenter, phase II dou-
ble-blind, placebo controlled trial (NCT00554775). Multicenter 
ethics approvals were obtained, and written informed consent from 
all patients was obtained.
All patients received standard WBRT administered in 20 Gy in 
5 daily fractions, starting within 4 weeks of the baseline CT or MR 
brain scan. Simulation was mandatory for whole brain irradiation 
and immobilization was recommended. Treatment was delivered 
by linear accelerator of energy ranging from 4–8 MV photons.
Erlotinib or matched placebo tablets were taken once daily 
starting on day 1 of WBRT (continuing through weekends). 
During WBRT the erlotinib dose was 100 mg/day (this dose was 
chosen because of concerns over possible neurotoxicity when the 
trial was designed). After completing WBRT the erlotinib dose was 
increased to the standard 150mg/day, until disease progression with 
symptomatic deterioration. The dose could be reduced or stopped 
following grade 3 or 4 adverse events that were not controlled by 
optimal supportive care.
Steroids were limited to dexamethasone; at least 4 mg were pre-
scribed during WBRT and for one week after. If medically feasible, 
the dose was then reduced according to local policy.
Assessments
Within 4 weeks before starting treatment, patients had a physical 
examination, full blood count, serum chemistry, chest X-ray, CT or 
MRI scan of the brain, and CT scan of the body. A clinical examina-
tion, the mini mental state examination (MMSE), and assessment of 
motor strength, visual acuity and gait (MVG) were completed before 
random assignment, two weekly for the first 8 weeks, then monthly 
until 12  months, and then two-monthly until death. Biological 
marker assessments, consisting of blood samples and diagnostic tis-
sue (where available), were collected before random assignment. 
Quality of life (QoL) assessments, using the EuroQol EQ- 5D ques-
tionnaire, were made before random assignment, monthly for the 
first 12 months, and then at 18 and 24 months after random assign-
ment. Adverse events were recorded up to 28  days after finishing 
erlotinib treatment, and graded using the National Cancer Institute 
Common Terminology Criteria of Adverse Events (version 3).
Translational Research
Sufficient diagnostic biopsy material (paraffin blocks) and DNA 
were available for 35 patients of 36 who provided blocks. The DNA 
extraction was performed using Qiagen FFPE DNA Extraction 
Kit. EGFR analysis was performed using Qiagen EGFR RGQ poly-
merase chain reaction (PCR) Kit for real-time PCR analysis of 29 
somatic mutations in the EGFR gene (Qiagen, Hilden, Germany).
Statistical Analysis
The primary endpoint was 2-month neurological progression-free 
survival (nPFS), defined as evidence of either clinical or radiological 
progression, ie, any one of the following: a loss of 3 points on the 
MMSE questionnaire compared to baseline; a loss of 3 points on the 
central nervous system (CNS) scale for MVG or a loss of 2 points for 
VG (ie, visual acuity & gait assessed by telephone) when compared 
to baseline; a deterioration of 10 or more points in Karnofsky perfor-
mance status, compared to baseline, at the 6 week assessment or later; 
an increase in dexamethasone dose suggestive of progressive disease 
at the 6 week assessment or later; an increase of 20% or greater in 
the sum of the longest diameters (LDs) of all metastases present at 
a baseline of 0.5 cm or greater, taking as reference the smallest sum 
LD recorded since the start of treatment; or the appearance of a new 
metastasis. Other end points included overall survival (OS), adverse 
events, and QoL.
A Simon minimax two-stage design for phase II studies was used, 
to detect a neurological PFS rate at 2 months of 65% or greater with 
erlotinib, assuming that neurological PFS is less than 50% among 
patients treated with WBRT only. Using a one-sided 10% statistical 
significance level and 90% power, the target accrual was 40 patients 
in the erlotinib arm in the first stage. If, after 2 months, 20 or more 
patients were alive and neurological progression-free the trial would 
continue to the second phase and recruit an additional 32 patients for 
each arm. The same number of placebo patients was specified (ie, a 
Table 1. Baseline characteristics
Variable
WBRT+placebo  
(n = 40)*
WBRT+erlotinib 
(n = 40)†
No. (%) No. (%)
Age at random assignment, y
 Median 62.2 61.3
 Range 41 - 73 48 - 75
Sex
 Female 19 (47.5) 25 (62.5)
 Male 21 (52.5) 15 (37.5)
Age-modified RTOG RPA‡
 I 8 (20.0) 10 (25.0)
 II 32 (80.0) 30 (75.0)
Brain metastases, no.
 ≤3 26 (65.0) 23 (57.5)
 >3 14 (35.0) 17 (42.5)
Extra-cranial metastases
 Absent 16 (40.0) 15 (37.5)
 Present 24 (60.0) 25 (62.5)
Karnofsky performance score
 70 13 (32.5) 9 (22.5)
 80 15 (37.5) 22 (55.0)
 90 9 (22.5) 9 (22.5)
 100 3 (7.5) 0 (0.0)
Histology
 Adenocarcinoma 20 (50.0) 23 (57.5)
 Squamous 7 (17.5) 5 (12.5)
 Other 6 (15.0) 5 (12.5)
 Unspecified 7 (17.5) 7 (17.5)
* One patient died before treatment, and one patient progressed before 
treatment.
† Three patients died before treatment.
‡ Radiation Therapy Oncology Group Recursive Partitioning Analysis.
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total target of 80 patients in the first stage). The data was reviewed at 
the end of the first stage by an independent data monitoring commit-
tee (IDMC) and all analyses were performed on an intention-to-treat 
basis. Hazard ratios (HRs), with 95% confidence intervals (CIs) and 
two-sided P values, were calculated using the Cox proportional hazards 
model. Survival curves are presented using the Kaplan-Meier method. 
Patients were censored using the date they were last seen if no event 
had occurred. Analysis was performed on an intention-to-treat (ITT) 
basis and generated using SAS software version 9.3 (SAS Institute, 
Cary, NC).
results
Eighty patients were recruited (June 2009 to June 2010) from 18 
centers across the UK National Cancer Research Network: 40 pla-
cebo and 40 erlotinib. Table 1 shows the baseline characteristics, 
and Figure 1 the CONSORT diagram.
Treatment Compliance
Seventy-five patients (94%) started trial treatment (n  =  5 had either 
died or progressed beforehand). Median time on the study drug was 
1.3 (placebo) and 1.8 (erlotinib) months. Thirty-one patients in each 
group (78%) took their erlotinib/placebo tablets for at least 75% of the 
time they were in the trial, ie, until they died/stopped treatment early 
(Supplementary Table 1, available online). Two patients in the placebo 
arm and 3 in the erlotinib arm temporarily stopped the study drug at 
7 or later days. Only one patient in the erlotinib arm experienced toxicity 
leading to a dose reduction from 150 to 100 mg daily (due to skin rash).
One patient (erlotinib) did not receive any WBRT. Six patients 
(placebo) and 5 patients (erlotinib) did not receive WBRT for 5 
consecutive days excluding weekends (Figure 1).
Efficacy
Fifteen patients (37.5%) in each treatment group were alive and 
free from neurological progression at 2  months, less than the 
Available for follow up 
(n = 40)
Ineligible (n = 1)*: 
Presence of solitary brain metastasis suitable 
for stereotactic radiosurgery / surgical resection 
& withdrawn after 3 weeks 
WBRT + placebo (n = 40) 
Received placebo (n = 38) 
No trial treatment (n = 2):  
- died before treatment (1) 
- progressed before treatment (1) 
Did not WBRT for 5 consecutive days (n = 6): 
 - administrative or technical reasons (3) 
 - RT related toxicity (1) 
 - bank holiday (2) 
Ineligible (n = 0) 
WBRT + erlotinib  (n = 40) 
Received erlotinib  (n = 37) 
No trial treatment (n = 3): 
 - died before treatment (3) 
Did not receive WBRT (n = 1) 
Did not WBRT for 5 consecutive days (n = 5): 
 - administrative or technical reasons (3) 
 - delayed consent (1) 
- machine capacity (1)
Available for follow up 
(n = 40)
Randomly allocated 
(N = 80) 
Available for analysis 
(n = 40)
Available for analysis 
(n = 40)
Figure 1. CONSORT diagram, including the number of patients who started and continued trial treatment, and the reasons for stopping early.
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target of 20 or greater, so the IDMC recommended not proceed-
ing to stage 2.
The median follow up was 12.6  months (censoring those 
who had died). There were 35 placebo and 38 erlotinib patients 
who had died or had neurological progression, with median 
neurological PFS of 1.6 months in each group (Figure 2). The 
2-month PFS rate was 38.9%, 95% CI = 23.6% to 54.2% (erlo-
tinib), compared to 38.5%, 95% CI = 23.2% to 53.7% (placebo).
Figure 2. A) Neurological progression-free survival (NPFS) and B) overall survival (OS) curves according to treatment arms in all patients. The 
number of patients at risk in each group at various time points is located under each graph.
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The unadjusted HR for neurological PFS was 0.99 (95% 
CI = 0.62 to1.58; P = .97), which became 0.95 (95% CI = 0.59 
to 1.54; P =  .84) after allowing for the randomization strati-
fication factors. The adjusted HR among the 75 patients 
who started the study drug was 0.89 (95% CI = 0.54 to 1.46; 
P = .65).
Sixty-six patients died (31 placebo and 35 erlotinib), with a 
median OS of 2.9 and 3.4  months, respectively (Figure  2). The 
unadjusted OS HR was 0.94 (95% CI = 0.58 to 1.54; P = .81), and 
0.95 (95% CI = 0.58 to 1.55; P = .83) after allowing for stratifica-
tion factors. The adjusted HR among the 75 patients who started 
the study drug was 0.90 (95% CI  =  0.54 to1.51; P  =  .69). The 
6-month OS rates for RTOG RPA class  I  patients were: 56.3% 
(placebo arm, n = 8 and 3 deaths); and 45.0% (erlotinib arm, n = 10 
and 8 deaths). For RTOG class II patients, the rates were: 24.3% 
(placebo n = 32 and 28 deaths); and 16.6% (erlotinib, n = 30 and 27 
deaths) (Supplementary Figure 1, available online).
Toxicity
Twenty-eight (70.0%) patients suffered a grade 3 or 4 adverse event 
in each treatment group (Table 2). More patients in the erlotinib 
group experienced rash as expected (20.0% vs 5.0%); and fewer 
erlotinib patients had grade 3/4 fatigue (17.5% vs 35.0%). No sus-
pected unexpected serious adverse reactions were reported.
Quality of Life
There was no evidence of differences in the QoL scores between 
treatment groups at one or two months, adjusting for baseline 
scores (all P ≥ .40) (Supplementary Table 2, available online).
Biological Substudy
The activating EGFR mutation-positive rate was only 2.9% (1/35). 
This patient had a neurological PFS time of 1.3 months and sur-
vived 1.6 months after random assignment.
Discussion
We showed that concurrent erlotinib with WBRT followed by 
maintenance erlotinib did not improve neurological PFS or OS in 
our patients with multiple brain metastases. The median neurologi-
cal PFS and OS in this group were disappointingly low; 1.6 months 
and 3.4  months respectively, despite selecting only patients with 
age-modified RTOG RPA class I and II.
However, a recent single arm phase II trial (40 patients) of 
erlotinib plus concurrent WBRT reported a median survival of 
11.8 months and a high intracranial response rate, but more than 
50% of patients had activating EGFR mutations. Similar to our 
study, they found erlotinib with WBRT was well tolerated with 
no unexpected neurotoxicity (24). In another phase II study, 28 
NSCLC patients harboring EGFR mutations were treated with 
either gefitinib or erlotinib alone (25). Response rates in the brain 
were high, with 23 patients (83%) achieving a partial response, 
with a median progression-free survival of 6.6 months, and an OS 
of 15.9  months. Both studies showed encouraging results with 
EGFR tyrosine-kinase inhibitors (TKIs) with or without WBRT in 
patients with activating EGFR mutation tumors in contrast to our 
study where patients had predominantly wild-type EGFR tumors. 
There have been several case reports describing disease response in 
the brain metastases harboring EGFR mutations with TKI alone, 
and also that refractory CNS and lepto-meningeal metastases can 
be improved by escalating the dose of erlotinib, correlated with 
higher cerebrospinal fluid (CSF) concentrations (19–22, 26, 27).
In contrast to Welsh et al (24), we found the frequency of EGFR 
mutations in our treated patients was low (3%). This low frequency 
mutation rate was similar to that reported in another recent study exam-
ining the frequency of EGFR mutations in brain metastases among 
NSCLC patients (28). In 77 brain tumor samples, the rate of EGFR 
mutations was 3.9% (3/77) in contrast to a KRAS mutation rate of 39% 
(30/77). The lack of anti-brain metastasis activity in EGFR wild-type 
tumors is compatible with a reported retrospective study. This study of 
69 NSCLC patients with brain metastases found responses were only 
observed in patients with activating EGFR mutation (82%) but not 
wild-type tumors (22). Additionally, median time to progression within 
the brain and OS were 5.8 and 3.1  months for unselected patients, 
compared to 11.7 and 12.9 months, respectively, for patients harbor-
ing EGFR mutations. We hypothesize that for EGFR wild-type tumors, 
erlotinib concentration achieved in the CSF is sub-therapeutic and also 
too low to exert radio-sensitizing activity. Further research could explore 
escalating the erlotinib dose before WBRT or strategies to disrupt the 
blood-brain barrier in order to increase erlotinib CSF penetration.
We also found that overall median survival for unselected 
patients with multiple brain metastases treated with WBRT 
Table 2. Reported grade 3 or 4 toxicities
Variable
WBRT+placebo 
(n = 40)*
WBRT+erlotinib 
(n = 40)†
No. (%) No. (%)
Any toxicity (each patient 
counted once)
28 (70.0) 28 (70.0)
 Dyspnoea 15 (37.5) 14 (35.0)
 Fatigue 14 (35.0) 7 (17.5)
 Rash 2 (5.0) 8 (20.0)
 Infection 2 (5.0) 5 (12.5)
 Myopathy 4 (10.0) 2 (5.0)
 Anorexia 3 (7.5) 2 (5.0)
 Pain 3 (7.5) 2 (5.0)
 Diarrhoea 2 (5.0) 2 (5.0)
 Headache 4 (10.0) 0 (0.0)
 Muscle weakness 
(myopathy)
3 (7.5) 0 (0.0)
 Anaemia 2 (5.0) 0 (0.0)
 Dehydration 0 (0.0) 2 (5.0)
 Pulmonary embolism 1 (2.5) 1 (2.5)
 Seizure 2 (5.0) 0 (0.0)
 Somnolence 1 (2.5) 1 (2.5)
 Constipation 0 (0.0) 1 (2.5)
 Dry skin 0 (0.0) 1 (2.5)
 Nausea 0 (0.0) 1 (2.5)
 Pneumonitis 1 (2.5) 0 (0.0)
 Other 9‡ (22.5) 10║ (25.0)
* One patient died before treatment, and one patient progressed before 
treatment.
† Three patients died before treatment.
‡ Ataxia, facial oedema, fainted, fractured humerus, hydrocephalus, low 
haemoglobin, neuropathy-motor, pleural effusion, urinary retention.
║ Alopecia, aspiration, dysasthria, dyspepsia, expressive dysphasia, 
hyperglycemia, hypotension, metabolic acidosis, pancreatitis, raised alanine 
transaminase.
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alone was low (2.9  months) despite selecting only patients with 
Karnofsky performance statuses of 70 and greater (23). Welsh et al 
(24) used 3000cGy WBRT in 10 fractions, and we used 2000cGy 
WBRT in five fractions, but this is unlikely to be the main reason 
why our patients had a poor survival. Previous trials and a system-
atic review reported no improvement in the frequency and dura-
tion of response, survival or QoL for radiation doses ranging from 
20 Gy in five fractions to 50 Gy in 20 fractions (5, 29, 30). The 
RTOG report that patients had a median survival of 7.1, 4.2 and 
2.3  months for classes I, II and III, respectively. The sole crite-
rion required to classify a patient in the poorest prognostic group 
(class III) is a KPS of less than 70. Despite excluding patients with 
KPS of less than 70, the median OS in our trial was similar to that 
reported for RPA class  III. The three-tier RTOG RPA prognos-
tic classification, based on several cancers (lung, breast, melanoma, 
colorectal, and others), may not be entirely applicable to NSCLC 
patients with multiple brain metastases.
Our finding does not preclude the possibility that erlotinib is 
effective for EGFR mutation positive tumors as only 2.9% of assessed 
patients manifested EGFR mutations. Future studies should focus 
on the role of erlotinib with or without WBRT in NSCLC patients 
harboring EGFR mutations. This includes comparing erlotinib 
alone with WBRT plus erlotinib, erlotinib alone with stereotactic 
radiotherapy or surgery for patients with 3 or fewer brain metas-
tases, escalating the dose of erlotinib in patients with CNS relapse 
after TKI treatment, or strategies to disrupt blood brain barrier in 
order to increase erlotinib delivery to the brain.
In conclusion, we showed no statistically significant improve-
ment in neurological PFS or OS in unselected patients treated 
with concurrent erlotinib and WBRT followed by maintenance 
erlotinib compared to placebo.
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